Generic Name and Formulations:
Mesna 400mg; tabs.
Indications for MESNEX:
Prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
See literature. IV Schedule: Give as IV bolus injection in a dosage equal to 20% of the ifosfamide dose at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide; total daily dose is 60% the ifosfamide dose. IV and oral dosing: Give as IV bolus injection in a dosage equal to 20% of the ifosfamide dose at the time of ifosfamide administration, followed by the tablets given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide; total daily dose is 100% of the ifosfamide dose. Repeat schedule on each day ifosfamide is given. If vomiting occurs within 2hrs of oral mesna, repeat dose or give IV mesna.
Hypersensitivity to thiol compounds.
Monitor morning specimen of urine for the presence of hematuria each day prior to ifosfamide therapy; consider dose reduction or discontinue if hematuria occurs. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
GI upset, fever, anorexia, flatulence, constipation, rhinitis, rigors, back pain, rash, conjunctivitis, arthralgia, headache, inj site reactions, flushing, dizziness, pharyngitis, hyperaesthesia, flu-like symptoms, coughing; hypersensitivity reactions.
Patients taking mesna should drink at least a quart of liquid a day.
Tabs—10; Multidose vials—1, 10
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness